Search Results - technology+classifications+%3e+healthcare+portfolios+%3e+infectious+diseases

41 Results Sort By:
Use of DNA Containing Specific Sequences to Prevent Neisseria Gonorrhoeae Infection
This invention encompasses an antimicrobial that can treat disease caused by the pathogen Neisseria Gonorrhoeae (Ngo). The compounds described can be incorporated into commercially available personal lubricants for individual use. Background: N. gonorrhoeae (Ngo) causes over 160 million new cases of gonorrhea each year globally; in 2018, it caused...
Published: 5/6/2022   |   Inventor(s): Magdalene So, Maria Rendon
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Infectious Diseases
Genes and Polypeptides of Neisseria Musculi that can be used to Evaluate Vaccines and Anti-Bacterial Compounds against Infection by Pathogenic Neisseria Species
A set of Neisseria musculi (Nmus) genes have been identified which promote Nmus infection and persistence in its natural host, the mouse. These genes have never been described before, so the in-host function of their encoded proteins is unknown. These genes are present in the human pathogenic Neisseria, N. meningitidis and N. gonorrhoeae. These genes...
Published: 5/6/2022   |   Inventor(s): Magdalene So, Katherine Rhodes, Maria Rendon
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Therapeutics
Direct Capture and Smartphone Quantification of Airborne SARS-CoV-2 on a Paper Microfluidic Chip
This is a rapid, handheld smartphone-based paper microfluidic assay that is capable of directly detecting SARS-CoV-2 in small droplets from the air, without the need for an air sampler or a long collection time. The infected droplets are collected on a paper microfluidic chip, which then has antibody-conjugated submicron fluorescent particle suspension...
Published: 1/19/2022   |   Inventor(s): Jeong-Yeol Yoon
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Diagnostics, Technology Classifications > Healthcare Portfolios > Infectious Diseases
Novel Antibiotic Drug Combination Including an Anti-Inflammatory Metabolite
This technology involves a combination of a metabolite, 3-hydroxyanthanilic acid (3HAA) with a compound that alters cellular iron homeostasis (e.g. an iron chelator or an iron supplement) that produces synergistic antibiotic interaction. 3HAA sensitizes bacteria to changes in iron availability (both increasing iron media content through supplementation...
Published: 11/12/2021   |   Inventor(s): George Sutphin, Luis Espejo
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
Covid-19 Time of Intubation Mortality Evaluation (C-TIME)
This invention describes software that uses a scoring system for calculating the probable mortality of patients with COVID-19 pneumonia at the time they require mechanical ventilation. Background: Worldwide there have been over 208 million cases of severe acute respiratory coronavirus 2 (SARS-CoV-2) and over 4.37 million of these cases resulted in...
Published: 9/30/2021   |   Inventor(s): Craig Heise, Robert A. Raschke, Pooja Rangan, Sumit Agarwal, Suresh Uppalapu, Nehan Sher
Keywords(s):  
Category(s): Technology Classifications > Software & Information Technology > Health IT, Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Healthcare Portfolios > Respiratory & Pulmonary, Technology Classifications > Healthcare Portfolios > Emergency Medicine
A Microbiome Sparing, Organism-Specific Therapy for C. difficile Infection
This technology introduces a water-soluble nanocarrier that is non-toxic to both human tissue and to bacteria. The carrier can complex with oligonucleotides and deliver targeted moieties to modify various bacterial functions. This technology is a platform that would allow for treatment of more than just C. difficile, specific species of bacteria can...
Published: 7/7/2021   |   Inventor(s): David Stewart, Arun Sharma, Gayatri Vedantam
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Infectious Diseases
Ait1 Protein to Control Eukaryote Metabolism
This invention provides compositions and methods for treating fungal or yeast infections using a previously unstudied GPCR-like protein which is integral to the regulation of cell growth in yeast cells. This protein and metabolic pathway is absent in higher-order animals, which provides a novel pathway for drugs to stop the growth of deadly fungal...
Published: 4/26/2021   |   Inventor(s): Andrew Capaldi, Ryan Wallace, Eric Lu
Keywords(s):  
Category(s): Technology Classifications > Research Tools > Screening assays, Technology Classifications > Research Tools > Protein, Technology Classifications > Veterinary Medicine > Therapeutics & Vaccines, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Infectious Diseases
Discovery of Pyrazolopyridine Analogs as Broad-Spectrum Antivirals against Non-Polio Enteroviruses including EV-D68, EV­A71, and CVB3
This invention reports the discovery and development of pyrazolopyridine inhibitors that have been shown to be effective in cell culture against multiple strains of non-polio enteroviruses including: EV-D68, EV­A71, and CVB3. There are currently no antivirals or vaccines for non-polio enteroviruses, and the health consequences of infection for some...
Published: 4/9/2021   |   Inventor(s): Jun Wang, Naoya Kitamura
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Healthcare Portfolios > Infectious Diseases
PLpro Inhibitors Against SARS-CoV-2
There are two cysteine proteases that are encoded by SARS-CoV-2, the main protease (Mpro) and the papain-like protease (PLpro). Both of these proteases have been shown to be essential in viral replication and are validated antiviral drug targets. PLpro cleaves the viral SARS-CoV-2 polyprotein at three sites. In addition, it modulates host immune response...
Published: 3/23/2021   |   Inventor(s): Jun Wang, Chunlong Ma, Naoya Kitamura, Yanmei Hu
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Small Molecules
Treatment of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) with a Polypeptide
The SARS-CoV-2 virus binds to ACE2, a cell surface protein receptor. The ACE2 binding reduces the ability of ACE2 to break down Angiotensin-II (Ang-II). Ang-II is a potent vasoconstrictor that can increase lung injury and lung edema, increase blood pressure, and can be harmful to organ function at high concentrations. This technology administers a...
Published: 1/20/2021   |   Inventor(s): Kathleen Rodgers, Sairam Parthasarathy, Gere deZerega
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Infectious Diseases
1 2 3 4 5